In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

British industry leaders fear tariffs imposed by President Trump could disrupt the supply and even the price of drugs ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Emergency room visits attributed to popular weight loss drugs such as Ozempic and Wegovy remain quite rare overall, but do ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...